Century Therapeutics, Inc. (NASDAQ:IPSC) Insider Gregory Russotti Sells 5,000 Shares

Century Therapeutics, Inc. (NASDAQ:IPSC) insider Gregory Russotti sold 5,000 shares of the business’s stock in a transaction on Monday, May 6th. The stock was sold at an average price of $3.12, for a total value of $15,600.00. Following the transaction, the insider now owns 292,319 shares of the company’s stock, valued at approximately $912,035.28. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Gregory Russotti also recently made the following trade(s):

• On Monday, April 22nd, Gregory Russotti sold 5,000 shares of Century Therapeutics stock. The shares were sold at an average price of $3.10, for a total transaction of $15,500.00.

Century Therapeutics Price Performance

Shares of IPSC stock traded up $0.20 on Tuesday, hitting $3.37. The company’s stock had a trading volume of 113,352 shares, compared to its average volume of 192,667. Century Therapeutics, Inc. has a fifty-two week low of $1.28 and a fifty-two week high of $5.51. The firm’s fifty day moving average price is $3.90 and its 200-day moving average price is $3.22. The stock has a market capitalization of $218.44 million, a price-to-earnings ratio of -1.44 and a beta of 1.44.

Century Therapeutics (NASDAQ:IPSC) last posted its quarterly earnings data on Thursday, March 14th. The company reported ($0.49) EPS for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.07. Century Therapeutics had a negative return on equity of 54.73% and a negative net margin of 6,115.12%. The business had revenue of $0.27 million for the quarter, compared to analyst estimates of $1.69 million. Analysts predict that Century Therapeutics, Inc. will post -1.94 EPS for the current fiscal year.

Hedge Funds Weigh In On Century Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Federated Hermes Inc. lifted its position in Century Therapeutics by 0.4% in the fourth quarter. Federated Hermes Inc. now owns 618,482 shares of the company’s stock worth $2,053,000 after purchasing an additional 2,500 shares during the period. Avidity Partners Management LP raised its stake in shares of Century Therapeutics by 23.4% in the 4th quarter. Avidity Partners Management LP now owns 1,355,000 shares of the company’s stock valued at $4,499,000 after buying an additional 256,500 shares in the last quarter. Abel Hall LLC bought a new position in shares of Century Therapeutics during the 4th quarter worth about $33,000. Finally, Mirae Asset Global Investments Co. Ltd. bought a new stake in Century Therapeutics in the first quarter valued at about $47,000. 50.20% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research analysts have commented on IPSC shares. Canaccord Genuity Group raised their target price on shares of Century Therapeutics from $22.00 to $24.00 and gave the stock a “buy” rating in a report on Friday, March 15th. HC Wainwright reaffirmed a “buy” rating and set a $13.00 price objective on shares of Century Therapeutics in a research report on Friday, March 15th. Finally, Piper Sandler reissued an “overweight” rating and set a $9.00 target price (down previously from $10.00) on shares of Century Therapeutics in a research note on Friday, April 12th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $13.60.

Century Therapeutics Company Profile

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.